Expertise in
3
conditions

Dr. James A. Reeves

Oncology | Hematology
8260 Gladiolus Dr, 
Fort Myers, FL 
Expertise in
3
conditions
8260 Gladiolus Dr, 
Fort Myers, FL 

Overview

James Reeves is an Oncologist and a Hematologist in Fort Myers, Florida. Dr. Reeves is highly rated in 3 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Myelodysplastic Syndrome (MDS), Lynch Syndrome, and Familial Colorectal Cancer.

His clinical research consists of co-authoring 29 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology
Hematology

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D

Locations

8260 Gladiolus Dr, Fort Myers, FL 33908

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: January 21, 2026
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drug: APG-115+Pembrolizumab
Study Phase: Phase 1/Phase 2
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drugs: Avelumab, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

29 Total Publications

Personalized Therapy Selection by Integration of Molecular Cancer Classification by the 92-Gene Assay and Tumor Profiling in Patients With Cancer of Unknown Primary.
Personalized Therapy Selection by Integration of Molecular Cancer Classification by the 92-Gene Assay and Tumor Profiling in Patients With Cancer of Unknown Primary.
Journal: JCO precision oncology
Published: September 04, 2024
Similar Doctors
Expertise in
31
conditions
Dr. Lowell L. Hart
Hematology | Oncology
Expertise in
31
conditions
Dr. Lowell L. Hart
Hematology | Oncology

Florida Cancer Specialists Pl

8260 Gladiolus Dr, 
Fort Myers, FL 
 (0.1 miles away)
239-437-5755
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lowell Hart is a Hematologist and an Oncologist in Fort Myers, Florida. Dr. Hart is highly rated in 31 conditions, according to our data. His top areas of expertise are Breast Cancer, Lung Cancer, Inflammatory Breast Cancer, and Paget Disease of the Breast. Dr. Hart is currently accepting new patients.

Expertise in
22
conditions
Dr. William Harwin
Hematology | Oncology
Expertise in
22
conditions
Dr. William Harwin
Hematology | Oncology

Florida Cancer Specialists & Research Institute LLC

8260 Gladiolus Dr, 
Fort Myers, FL 
 (0.1 miles away)
239-437-5755
Languages Spoken:
English
See accepted insurances

William Harwin is a Hematologist and an Oncologist in Fort Myers, Florida. Dr. Harwin is highly rated in 22 conditions, according to our data. His top areas of expertise are Paget Disease of the Breast, Inflammatory Breast Cancer, Lung Cancer, and Pleuropulmonary Blastoma.

Expertise in
65
conditions
Dr. Syed F. Zafar
Hematology | Oncology
Expertise in
65
conditions
Dr. Syed F. Zafar
Hematology | Oncology

Florida Cancer Specialists Pl

1708 Cape Coral Pkwy W Ste 10, 
Cape Coral, FL 
 (7.8 miles away)
239-541-4633
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Syed Zafar is a Hematologist and an Oncologist in Cape Coral, Florida. Dr. Zafar is highly rated in 65 conditions, according to our data. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Paget Disease of the Breast, and Familial Colorectal Cancer. Dr. Zafar is currently accepting new patients.

Frequently Asked Questions about Dr. James A. Reeves

How do I make an appointment with Dr. James A. Reeves?

You can book an appointment with Dr. James A. Reeves by calling their office at 239-437-5755. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. James A. Reeves a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. James A. Reeves is classified as an Advanced expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. James A. Reeves specialize in?

While Dr. James A. Reeves is a Oncology, they have specific expertise in Colorectal Cancer, Myelodysplastic Syndrome (MDS), and Lynch Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. James A. Reeves participate in research or clinical trials?

Yes. Dr. James A. Reeves has published 29 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. James A. Reeves's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. James A. Reeves accept my insurance?

Dr. James A. Reeves accepts most major insurance plans, including Humana and Medicare. We recommend calling the office directly at 239-437-5755 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Reeves's expertise for a condition
ConditionClose
      View All 68 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile